Abstract
Objective
To evaluate whether the single nucleotide polymorphism (SNP), rs1805415 in the PARP1 gene impact alone or in combination on overall survival (OS) in patients with bladder cancer of Gansu province.
Methods
The association between PARP1 genetic polymorphisms and clinicopathologic characteristics of 144 patients with BC was analyzed using QuantStudio™ 12K Flex Real-Time PCR System clamping.
Results
The PARP1 genotype had a notable impact on OS. Kaplan-Meier analysis estimates a decreasing OS (P=0.020) between CC, CT and TT genotype patients, survival curves were calculated for overall according to the PARP1 genotypes and between C-allele and T-allele. However, patients with TT genotype had significantly shorter survival time compared with the (CT + CC) genotype patients. In multivariate analysis, revealed that pathological classification (HR 4.183, 1.200–14.588; P=0.025), smoking status (HR 6.202, 1.014–37.914; P=0.048) and recurrence (HR 32.529, 3.397–311.535; P=0.003) were found to be a strong independent prognosticator with marked increased risk for poor OS in different genotype. Despite the close correlation between PARP1-SNP and survival in univariate analysis, there was no significant difference in the probabilities of overall survival between the genotypes (P=0.832) in this study cohort.
Conclusions
Analysis of genotypes and clinical data for bladder cancer patients indicates that the PARP1 rs1805415 genotype may be a useful prognostic genetic marker for bladder cancer.
Keywords: PARP1, polymorphism, bladder cancer, overall survival (OS)